21792802

Source:http://linkedlifedata.com/resource/pubmed/id/21792802

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0087111, umls-concept:C0205478, umls-concept:C0879626
pubmed:issue	15
pubmed:dateCreated	2011-7-27
pubmed:language	ger
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101468093
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates, http://linkedlifedata.com/resource/pubmed/chemical/EGFR protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Indoles, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles, http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus, http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab, http://linkedlifedata.com/resource/pubmed/chemical/cetuximab, http://linkedlifedata.com/resource/pubmed/chemical/erlotinib, http://linkedlifedata.com/resource/pubmed/chemical/everolimus, http://linkedlifedata.com/resource/pubmed/chemical/sorafenib, http://linkedlifedata.com/resource/pubmed/chemical/sunitinib, http://linkedlifedata.com/resource/pubmed/chemical/temsirolimus, http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	1661-8157
pubmed:author	pubmed-author:BudaiII, pubmed-author:PestalozziBB, pubmed-author:WeisshauptChCh
pubmed:issnType	Print
pubmed:day	27
pubmed:volume	100
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	885-91; quiz 890
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:21792802-Antibodies, Monoclonal, pubmed-meshheading:21792802-Antibodies, Monoclonal, Humanized, pubmed-meshheading:21792802-Antineoplastic Agents, pubmed-meshheading:21792802-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:21792802-Benzenesulfonates, pubmed-meshheading:21792802-Colonic Neoplasms, pubmed-meshheading:21792802-Diagnosis, Differential, pubmed-meshheading:21792802-Dose-Response Relationship, Drug, pubmed-meshheading:21792802-Drug Delivery Systems, pubmed-meshheading:21792802-Drug Eruptions, pubmed-meshheading:21792802-Facial Dermatoses, pubmed-meshheading:21792802-Humans, pubmed-meshheading:21792802-Indoles, pubmed-meshheading:21792802-Liver Neoplasms, pubmed-meshheading:21792802-Male, pubmed-meshheading:21792802-Middle Aged, pubmed-meshheading:21792802-Neoplasms, pubmed-meshheading:21792802-Pyridines, pubmed-meshheading:21792802-Pyrroles, pubmed-meshheading:21792802-Quinazolines, pubmed-meshheading:21792802-Receptor, Epidermal Growth Factor, pubmed-meshheading:21792802-Sirolimus
pubmed:year	2011
pubmed:articleTitle	[Adverse effects of new oncologic therapies].
pubmed:affiliation	Klinik und Poliklinik für Innere Medizin, Universitätsspital Zürich.
pubmed:publicationType	Journal Article, Case Reports